Hemophilia B Gene Therapy Among Five Drugs On Track For EU-Wide Approval

Alongside CSL/Behring/uniQure’s Hemgenix (etranacogene dezaparvovec), the European Medicines Agency has given the green light to new drugs for liver cancer, NSCLC, Pompe disease and multiple sclerosis. But it turned down omburtamab for treating the rare cancer, neuroblastoma.  

Blood Sample for Factor IX. Blood coagulation testing.
Hemophilia B is a genetic disorder caused by a missing or defective factor IX clotting protein • Source: Shutterstock

The European Medicines Agency’s human drugs committee, the CHMP, has recommended EU approval of CSL Behring/uniQure’s Hemgenix (etranacogene dezaparvovec), the first gene therapy for treating patients with hemophilia B.

It has also given a positive opinion on two products from AstraZeneca containing tremelimumab: Imjudo for use in adults...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography